ICB plus radiotherapy is supported for NSCLC patients with high cardiovascular risk, whereas ROS1/NTRK/MET inhibitors and platinum-taxane chemotherapy warrant caution for cardiotoxicity.
How do different cancer therapies affect the risk of cardiotoxicity in patients with non-small cell lung cancer?
In patients with NSCLC, treatment selection should be guided by baseline cardiovascular risk, favoring ICB plus RT in high-risk patients and avoiding anti-PD-1 in those at risk for pericardial toxicity.
Absolute Event Rate: 0% vs 0%
These findings support the use of ICB plus RT in patients with high cardiovascular risk, while caution is advised with ROS1/NTRK/MET inhibitors and platinum-taxane chemotherapy. Anti-PD-L1 and anti-CTLA-4 may be preferred over anti-PD-1 in patients at risk for pericardial toxicity.
Mo et al. (Tue,) reported a other. ICB plus radiotherapy is supported for NSCLC patients with high cardiovascular risk, whereas ROS1/NTRK/MET inhibitors and platinum-taxane chemotherapy warrant caution for cardiotoxicity.